SequelSEC

Stereotaxis, Inc. STXS

Electromedical & Electrotherapeutic Apparatus · CIK 0001289340 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$7.67M
Fiscal year ended 2026-06-30
Operating income
-$4.57M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Stereotaxis, Inc. (STXS) reported revenue of $7.67M and net income of -$4.47M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Stereotaxis, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

Stereotaxis, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$7.67M$6.29M$8.64M$7.46M$8.80M$7.47M$6.34M$9.20M$4.50M$6.88M
Cost of revenue$3.18M$2.50M$4.32M$3.36M$4.22M$3.41M$3.12M$5.10M$1.19M$2.91M
Gross profit$4.49M$3.79M$4.33M$4.10M$4.58M$4.06M$3.22M$4.10M$3.31M$3.97M
Operating income-$4.57M-$5.98M-$5.65M-$6.56M-$3.98M-$5.93M-$7.63M-$6.34M-$6.02M-$4.75M
Net income-$4.47M-$5.86M-$5.53M-$6.46M-$3.83M-$5.82M-$7.52M-$6.19M-$5.83M-$4.51M
Research & development$2.39M$2.40M$2.71M$2.55M$1.78M$2.35M$2.79M$2.45M$2.27M$2.24M
Weighted-average diluted sharesshares 100.03Mshares 98.89MUnavailableshares 92.01Mshares 87.95Mshares 87.77MUnavailableshares 85.82Mshares 84.57Mshares 83.48M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.05$-0.06Unavailable$-0.07$-0.05$-0.07Unavailable$-0.08$-0.07$-0.06
Selling, general & administrative$6.66M$7.38M$7.27M$8.11M$7.27M$7.64M$8.05M$7.99M$7.06M$6.47M
General & administrative$4.07M$4.76M$4.17M$5.18M$4.00M$4.50M$5.14M$4.84M$3.76M$3.47M
Selling & marketing$2.60M$2.62M$3.09M$2.93M$3.27M$3.15M$2.92M$3.15M$3.30M$3.00M

Balance

Stereotaxis, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$10.49M$14.62M$13.42M$10.51M$6.97M$10.60M$12.22M$10.66M$14.68M$17.63M
Total assets$55.58M$54.03M$52.25M$45.59M$41.17M$45.70M$46.72M$50.94M$36.01M$39.45M
Current assets$37.99M$36.03M$33.85M$26.66M$21.90M$25.91M$26.44M$28.81M$28.07M$31.21M
Total liabilities$38.10M$34.43M$33.53M$34.05M$34.42M$37.53M$35.29M$34.71M$19.25M$19.42M
Current liabilities$26.80M$23.09M$22.36M$20.37M$20.75M$24.23M$21.60M$20.72M$12.25M$12.85M
Total equity incl. NCI$12.24M$14.36M$13.48M$6.27M$1.46M$2.88M$6.08M$10.82M$11.36M$14.57M
Temporary (mezzanine) equityUnavailableUnavailable$5.24M$5.27M$5.30M$5.30M$5.35M$5.41M$5.41M$5.46M
Inventory$12.52M$10.50M$9.57M$10.15M$9.61M$9.81M$8.33M$9.01M$9.28M$8.25M
Accounts receivable$7.55M$5.30M$5.85M$5.33M$4.39M$4.32M$3.82M$7.92M$2.78M$3.95M
Goodwill$3.76M$3.76M$3.76M$3.76M$3.76M$3.76M$3.76M$4.49MUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$6.87M$4.82M$4.77M$4.68M$6.73M$6.54M$5.67M$6.40M$4.15M$3.31M

Cash flow

Stereotaxis, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$3.68M-$3.44M-$3.97M-$4.20M-$3.73M-$1.78M$1.27M-$4.33M-$3.09M-$2.35M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$1.14M-$79.00K-$70.00K$0UnavailableUnavailable-$2.00K$98.00KUnavailableUnavailable
Financing cash flow$695.00K$4.72M$6.95M$7.74M$34.00K$32.00K$159.00K$80.00K$28.00K$30.00K
Net change in cash-$4.12M$1.20M$2.92M$3.54M-$3.72M-$1.75M$1.42M-$4.15M-$3.08M-$2.32M
Stock-based compensation$1.61M$2.11M$2.45M$2.50M$2.37M$2.54M$2.57M$2.57M$2.54M$2.59M
Common dividends paid$0$0$0$0$0$0$0$0$0$0
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Stereotaxis, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin58.5%60.3%50.1%54.9%52.0%54.4%50.7%44.6%73.6%57.6%
Operating margin-59.6%-95.1%-65.4%-87.8%-45.2%-79.3%-120.3%-69.0%-133.7%-69.0%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue21.0%33.5%28.3%33.5%26.9%33.9%40.5%27.9%56.4%37.6%
Current ratio1.42x1.56x1.51x1.31x1.06x1.07x1.22x1.39x2.29x2.43x
Revenue YoY growth-12.8%-15.8%36.3%-18.8%95.4%8.6%38.9%17.9%-42.7%5.1%
Net margin-58.3%-93.2%-64.0%-86.6%-43.5%-77.9%-118.5%-67.3%-129.6%-65.5%
R&D / revenue31.2%38.1%31.4%34.1%20.2%31.5%44.0%26.7%50.5%32.6%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open STXS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2026-06-30

Difference 5234000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2026-03-31

Difference 5240000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.